INTEGRILIN eptifibatide (as acetate) 20mg/10mL    injection vial Australië - Engels - Department of Health (Therapeutic Goods Administration)

integrilin eptifibatide (as acetate) 20mg/10ml injection vial

merck sharp & dohme (australia) pty ltd - eptifibatide, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide - integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials). indications as at 29 november 2001: integrilin is indicated for patients undergoing nonurgent percutaneous coronary intervention with intracoronary stenting (see clinical trials). integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials).

HEPARIN SODIUM injection, solution Verenigde Staten - Engels - NLM (National Library of Medicine)

heparin sodium injection, solution

mylan institutional llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin sodium injection is indicated for: the use of heparin sodium injection is contraindicated in patients with the following conditions: risk summary there are no available data on heparin sodium use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. in published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. no teratogenicity, but early embryo-fetal death was observed in animal reproduction studies with administration of heparin sodium to pregnant rats and rabbits during organogenesis at doses approximately 10 times the maximum recommended human dose (mrhd) of 45,000 units/day (see data ). consider the benefits and risks of heparin sodium injection for the mother and possible risks to the fetus when prescribing heparin sodium injection to a pregnant woman. if available, preservative-free heparin sodium injection is recommended when heparin therapy is needed during pregnancy. the

Integrilin Europese Unie - Engels - EMA (European Medicines Agency)

integrilin

glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - antithrombotic agents - integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ecg changes and / or elevated cardiac enzymes.patients most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (ptca).

INTEGRILIN SOLUTION Canada - Engels - Health Canada

integrilin solution

merck canada inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

INTEGRILIN SOLUTION Canada - Engels - Health Canada

integrilin solution

merck canada inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

INTEGRILIN IV BOLUS INJECTION 2 mgml Singapore - Engels - HSA (Health Sciences Authority)

integrilin iv bolus injection 2 mgml

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 2 mg/ml - eptifibatide 2 mg/ml

INTEGRILIN IV INFUSION 0.75 mgml Singapore - Engels - HSA (Health Sciences Authority)

integrilin iv infusion 0.75 mgml

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml

Integrilin Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

integrilin

merck sharp & dohme (new zealand) limited - eptifibatide 0.75 mg/ml - solution for injection - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

Integrilin Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

integrilin

merck sharp & dohme (new zealand) limited - eptifibatide 2 mg/ml - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.